ReviewOncolytic virotherapy2019
Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development.
Review in Oncolytic virotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Review
- Enhancing antitumor immunity through oncolytic viruses: advances in genetic engineering.Discover oncology · 2026Review
- Review
- Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms.Frontiers in immunology · 2025Review
- CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.Breast cancer research : BCR · 2024Article
- Exploring treatment options in cancer: Tumor treatment strategies.Signal transduction and targeted therapy · 2024Review
- Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.EBioMedicine · 2024Article
- STT3A-mediated viral N-glycosylation underlies the tumor selectivity of oncolytic virus M1.Oncogene · 2023Article
- Oncolytic virotherapy: basic principles, recent advances and future directions.Signal transduction and targeted therapy · 2023Review
- Pathological Characteristics of Echovirus 30 Infection in a Mouse Model.Journal of virology · 2022Article
- Atypical presentation of COVID-19: Chronic bilateral testicular pain with lower extremity peripheral polyneuropathy, case report.Urology case reports · 2022Article
- NK Cell Effector Functions and Bystander Tumor Cell Killing in Immunovirotherapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics.Frontiers in molecular biosciences · 2022Review
- Is there impact of the SARS-CoV-2 pandemic on steroidogenesis and fertility?Physiological research · 2021Review
- Cell surface heat shock protein-mediated entry of tumor cell-adapted rotavirus into U-937 cells.Folia microbiologica · 2021Article
- Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.International journal of molecular sciences · 2021Review
- Testicular pain as an unusual presentation of COVID-19: a brief review of SARS-CoV-2 and the testis.Reproductive biomedicine online · 2020Review
- Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B.Nature communications · 2020Article
- Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage.Nature communications · 2020Article
- Mechanisms involved in the development of thrombocytopenia in patients with COVID-19.Thrombosis research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advancements in oncolytic virotherapy commend a special attention to developing new strategies for targeting cancer cells with oncolytic viruses (OVs). Modifications of the viral envelope or coat proteins serve as a logical mean of repurposing viruses for cancer treatment. In this review, we discuss how detailed structural knowledge of the interactions between OVs and their natural receptors provide valuable insights into tumor specificity of some viruses and re-targeting of alternate receptors for broad tumor tropism or improved tumor selectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.